Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial
Adds background on data and disorder throughout
July 24 (Reuters) -Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
The data takes Pfizer one step closer to securing U.S. regulatory approval for a second gene therapy to treat hemophilia.
Pfizer had received the Food and Drug Administration's nod for Beqvez as a one-time gene therapy for hemophilia B, a less common type of the disorder, in April.
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Currently, the standard-of-care treatment for hemophilia A patients is to undergo routine replacement of the clotting protein called Factor VIII.
Pfizer said its gene therapy for hemophilia A not only met the main goal of showing non-inferiority compared to the Factor VIII replacement therapy in reducing the annual bleeding rate in patients, but also showed superiority to the current standard treatment.
Data from the 75-patient pool also showed that 84% of patients who were given Pfizer's gene therapy had Factor VIII levels above 5% at 15 months post-infusion, the company said.
The company will present additional data at upcoming medical meetings, it added. Pfizer is co-developing the hemophilia A gene therapy from with Sangamo Therapeutics SGMO.O, from whom it had licensed the therapy.
People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, leading to spontaneous as well as severe bleeding following injuries or surgery.
Hemophilia A affects about 25 in every 100,000 male births worldwide, according to data cited by Pfizer, with majority of them having a moderate to severe form of the disease for which the gene therapy was tested.
Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
